Search

Your search keyword '"Pierga, J.Y."' showing total 169 results
Start Over Author "Pierga, J.Y."
169 results on '"Pierga, J.Y."'

3. 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)

Author

Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C.H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M.J., Carey, L., Corneliussen-James, D., Curigliano, G., Dieras, V., El Saghir, N., Eniu, A., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Gennari, A., Harbeck, N., Hudis, C., Kaufman, B., Krop, I., Mayer, M., Meijer, H., Mertz, S., Ohno, S., Pagani, O., Papadopoulos, E., Peccatori, F., Penault-Llorca, F., Piccart, M.J., Pierga, J.Y., Rugo, H., Shockney, L., Sledge, G., Swain, S., Thomssen, C., Tutt, A., Vorobiof, D., Xu, B., Norton, L., and Winer, E.

Published
2017
Full Text
View/download PDF

5. Concurrent Olaparib with Radiotherapy in Patients with Triple Negative Breast Cancer: Final Results of the RADIOPARP Phase 1 Trial

Author

Loap, P., primary, Loirat, D., additional, Berger, F., additional, Rodrigues, M., additional, Bazire, L., additional, Pierga, J.Y., additional, Vincent-Salomon, A., additional, Laki, F., additional, Boudali, L., additional, Raizonville, L., additional, Mosseri, V., additional, Jochem, A., additional, Diallo, M., additional, Stern, M.H., additional, Fourquet, A., additional, and Kirova, Y., additional

Published
2022
Full Text
View/download PDF

6. Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: Experience of the REMAGUS 02 phase II trial

Author

Valet, F., de Cremoux, P., Spyratos, F., Servant, N., Dujaric, M.E., Gentien, D., Lehmann-Che, J., Scott, V., Sigal-Zafrani, B., Mathieu, M.C., Bertheau, P., Guinebretière, J.M., Pierga, J.Y., Delaloge, S., Giacchetti, S., Brain, E., Tembo, O., Marty, M., and Asselain, B.

Published
2013
Full Text
View/download PDF

11. One-Year Toxicity Report of the RADIOPARP Phase I Trial Evaluating Olaparib With Radiotherapy for Triple Negative Breast Cancer

Author

Loap, P., primary, Loirat, D., additional, Berger, F., additional, Rodrigues, M., additional, Bazire, L., additional, Pierga, J.Y., additional, Ricci, F., additional, Cao, K.I., additional, Vincent-Salomon, A., additional, Laki, F., additional, Ezzili, C., additional, Raizonville, L., additional, Mosseri, V., additional, Neffati, S., additional, Ezzalfani, M., additional, Fourquet, A., additional, and Kirova, Y., additional

Published
2021
Full Text
View/download PDF

13. Clinical utility of MammaPrint testing in Invasive Lobular Carcinoma: Results from the MINDACT phase III trial

Author

Metzger, O., primary, Cardoso, F., additional, Poncet, C., additional, Desmedt, C., additional, Linn, S., additional, Wesseling, J., additional, Hilbers, F., additional, Aalders, K., additional, Delorenzi, M., additional, Delaloge, S., additional, Pierga, J.Y., additional, Brain, E., additional, Vrijaldenhoven, S., additional, Neijenhuis, P.A., additional, Rutgers, E., additional, Piccart, M., additional, van ’t Veer, L., additional, and Viale, G., additional

Published
2020
Full Text
View/download PDF

14. Updated results of the MINDACT trial: 70-gene signature to guide de-escalation of chemotherapy in early breast cancer

Author

Rutgers, E.J.T., primary, van ’t Veer, L., additional, Poncet, C., additional, Cardozo, J.Lopes, additional, Delaloge, S., additional, Pierga, J.Y., additional, Vuylsteke, P., additional, Brain, E., additional, Viale, G., additional, Kümmel, S., additional, Rubio, I., additional, Zoppoli, G., additional, Thompson, A., additional, Zaman, K., additional, Knox, S., additional, Hilbers, F., additional, Peric, A., additional, Meulemans, B., additional, Piccart, M., additional, and Cardoso, F., additional

Published
2020
Full Text
View/download PDF

16. Corrigendum to '3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)' [Breast 31 (February 2017) 244-259]

Author

Cardoso, F., Costa, A., Senkus, E., Aapro, M., Andre, F., Barrios, C.H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M.J., Carey, L., Corneliussen-James, D, Curigliano, G, Dieras, V, El Saghir, N, Eniu, E, Fallowfield, L., Fenech, E, Francis, D, Gelmon, B, Gennari, D, Hudis, B, Kaufman, B., Krop, B, Meijer, D, Mertz, B, Ohno, B, Pagani, B, Papadopoulos, E., Peccatori, E, Penault-Llorca, L, Piccart, L, Pierga, D, Rugo, B, Shockney, L., Sledge, A, Swain, L, Thomssen, E, Tutt, L, Vorobiof, D., Xu, B., Norton, L., Winer, E., Eniu, A., Fenech, D., Francis, P., Gelmon, K., Gennari, A., Harbeck, N., Hudis, C., Krop, I., Mayer, M., Meijer, H., Mertz, S., Ohno, S., Pagani, O., Peccatori, F., Penault-Llorca, F., Piccart, M.J., Pierga, J.Y., Rugo, H., Sledge, G., Swain, S., Thomssen, C., Tutt, A., European School of Oncology & Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal, Champalimaud Clinical Center, European Institute of Oncology [Milan] (ESMO), Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland, Medical University of Gdansk, Breast Center, Genolier Cancer Center, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR), Department of Medicine, PUCRS School of Medicine, Department of Oncology–Pathology, Radiumhemmet, Karolinska University Hospital [Stockholm], Department of Medical Oncology, Fortis Hospital, 'Sandro Pitigliani' Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Breast Unit, Department of Hematology and Oncology, Lineberger Comprehensive Cancer Center (UNC Lineberger), University of North Carolina [Chapel Hill] (UNC), University of North Carolina System (UNC)-University of North Carolina System (UNC)-University of North Carolina [Chapel Hill] (UNC), University of North Carolina System (UNC)-University of North Carolina System (UNC), METAvivor Research and Support, MetaVivor Research and Support, Division of Experimental Therapeutics, Department of Medical Oncology, Institut Curie, Paris 75248, France, Brustzentrum der Universitat München, Universität München, Advanced BC.org, Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, business.industry, Advanced breast, Cancer, [SDV.CAN]Life Sciences [q-bio]/Cancer, General Medicine, medicine.disease, 3. Good health, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, Surgery, business, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

19. Trasutuzumab versus observation for high-risk, non-metastatic, HER2 non-amplified breast cancer with Circulating Tumor Cells (EORTC 90091-10093 Treat CTC): A European, multicenter, randomized phase 2 trial

Author

Ignatiadis, M., primary, Litiere, S., additional, Rothe, F., additional, Riethdorf, S., additional, Proudhon, C., additional, Fehm, T., additional, Aalders, K., additional, Forstbauer, H., additional, Fasching, P., additional, Brain, E., additional, Vuylsteke, P., additional, Guardiola, E., additional, Lorenz, R., additional, Pantel, K., additional, Tryfonidis, K., additional, Janni, W., additional, Piccart, M., additional, Sotiriou, C., additional, Rack, B., additional, and Pierga, J.Y., additional

Published
2018
Full Text
View/download PDF

20. Correction to: 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Author

Cardoso, F., primary, Costa, A., additional, Senkus, E., additional, Aapro, M., additional, André, F., additional, Barrios, C.H., additional, Bergh, J., additional, Bhattacharyya, G., additional, Biganzoli, L., additional, Cardoso, M.J., additional, Carey, L., additional, Corneliussen-James, D., additional, Curigliano, G., additional, Dieras, V., additional, El Saghir, N., additional, Eniu, A., additional, Fallowfield, L., additional, Fenech, D., additional, Francis, P., additional, Gelmon, K., additional, Gennari, A., additional, Harbeck, N., additional, Hudis, C., additional, Kaufman, B., additional, Krop, I., additional, Mayer, M., additional, Meijer, H., additional, Mertz, S., additional, Ohno, S., additional, Pagani, O., additional, Papadopoulos, E., additional, Peccatori, F., additional, Penault-Llorca, F., additional, Piccart, M.J., additional, Pierga, J.Y., additional, Rugo, H., additional, Shockney, L., additional, Sledge, G., additional, Swain, S., additional, Thomssen, C., additional, Tutt, A., additional, Vorobiof, D., additional, Xu, B., additional, Norton, L., additional, and Winer, E., additional

Published
2017
Full Text
View/download PDF

21. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)' [Breast 31 (February 2017) 244-259]

Author

Cardoso, F., Costa, A., Senkus, E., Aapro, M., Andre, F., Barrios, C.H., Bhattacharyya, G., Biganzoli, L., Cardoso, M.J., Carey, L., Corneliussen-James, D., Curigliano, G., Dieras, V., Saghir, N. El, Eniu, A., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Gennari, A., Harbeck, N., Hudis, C., Kaufman, B., Krop, I., Mayer, M., Meijer, H.J.M., Mertz, S., Ohno, S., Pagani, O., Papadopoulos, E., Peccatori, F., Penault-Llorca, F., Piccart, M.J., Pierga, J.Y., Rugo, H., Shockney, L., Sledge, G., Swain, S., Thomssen, C., Tutt, A., Vorobiof, D., Xu, B., Norton, L., Winer, E., Cardoso, F., Costa, A., Senkus, E., Aapro, M., Andre, F., Barrios, C.H., Bhattacharyya, G., Biganzoli, L., Cardoso, M.J., Carey, L., Corneliussen-James, D., Curigliano, G., Dieras, V., Saghir, N. El, Eniu, A., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Gennari, A., Harbeck, N., Hudis, C., Kaufman, B., Krop, I., Mayer, M., Meijer, H.J.M., Mertz, S., Ohno, S., Pagani, O., Papadopoulos, E., Peccatori, F., Penault-Llorca, F., Piccart, M.J., Pierga, J.Y., Rugo, H., Shockney, L., Sledge, G., Swain, S., Thomssen, C., Tutt, A., Vorobiof, D., Xu, B., Norton, L., and Winer, E.

Abstract

Item does not contain fulltext

Published
2017

24. Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution

Author

Bacrie, J., primary, Laurans, M., additional, Iorio, P., additional, Fourme, E., additional, Pierga, J.Y., additional, Béthune Volters, A., additional, Benzidane, B., additional, Bozec, L., additional, Lerebours, F., additional, Dubot, C., additional, Bensaoula, O., additional, and Lefeuvre, D., additional

Published
2017
Full Text
View/download PDF

25. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Author

Cardoso, F., primary, Costa, A., additional, Senkus, E., additional, Aapro, M., additional, André, F., additional, Barrios, C.H., additional, Bergh, J., additional, Bhattacharyya, G., additional, Biganzoli, L., additional, Cardoso, M.J., additional, Carey, L., additional, Corneliussen-James, D., additional, Curigliano, G., additional, Dieras, V., additional, El Saghir, N., additional, Eniu, A., additional, Fallowfield, L., additional, Fenech, D., additional, Francis, P., additional, Gelmon, K., additional, Gennari, A., additional, Harbeck, N., additional, Hudis, C., additional, Kaufman, B., additional, Krop, I., additional, Mayer, M., additional, Meijer, H., additional, Mertz, S., additional, Ohno, S., additional, Pagani, O., additional, Papadopoulos, E., additional, Peccatori, F., additional, Penault-Llorca, F., additional, Piccart, M.J., additional, Pierga, J.Y., additional, Rugo, H., additional, Shockney, L., additional, Sledge, G., additional, Swain, S., additional, Thomssen, C., additional, Tutt, A., additional, Vorobiof, D., additional, Xu, B., additional, Norton, L., additional, and Winer, E., additional

Published
2017
Full Text
View/download PDF

26. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Author

MINDACT Investigators, Benn, K., Bogaerts, J., Cardoso, F., Ciruelos, E., Corochan, S., Cuny, J., de la Pena, L., Delaloge, S., DeLorenzi, M., Dudek-Peric, A., Eekhout, I., Gluz, O., Golfinopoulos, V., Goulioti, T., Harbeck, N., Hilal, V., Knox, S., Lemonnier, J., Ławniczak, M., Marini, L., Matos, E., Morales, P., Murray, K., Nitz, U., Passalaqua, R., Piccart, M., Remmelzwaal, J., Rubio, I., Rutgers, E., Saghatchian, M., Slaets, L., Sotiriou, C., Straehle, C., Straley, M., Theron, N., Thompson, A., Tryfonidis, K., Todeschini, R., Urunkar, M., van 't Veer, L., Viale, G., Aalders, K., Bines, J., Bedard, P., Bozovic, I., Braga, S., Castaneda, C., Celebic, A., Colichi, C., Criscitiello, C., Dal Lago, L., Demonty, G., Drukker, C., Fei, F., Lia, M., Loi, S., Messina, C., Mook, S., Moulin, C., Sreseli, R., Therasse, P., Werutsky, G., Corachan, S., Wheeler, L., Dif, N., Rizzetto, G., Beauvois, M., Meirsman, L., Breyssens, H., Decker, N., Engelen, K., Akropovic, A., Harrison, J., Henot, F., Celis, M., De Jongh, B., Delmotte, I., Daubie, V., Goossens, R., Helsen, N., Hourt, L., Janssen, S., Soete, V., Vansevenant, K., Hermans, C., Hart, G., Brink, G., Floore, A., Sixt, B., Buyse, M., van't Veer, L.J., Pierga, J.Y., Brain, E., Causeret, S., Glas, A.M., Meulemans, B., Neijenhuis, P.A., Passalacqua, R., Ravdin, P., Rubio, I.T., Smilde, T.J., Stork, L., Thomas, G., Thompson, A.M., van der Hoeven, J.M., Vuylsteke, P., Bernards, R., MINDACT Investigators, Benn, K., Bogaerts, J., Cardoso, F., Ciruelos, E., Corochan, S., Cuny, J., de la Pena, L., Delaloge, S., DeLorenzi, M., Dudek-Peric, A., Eekhout, I., Gluz, O., Golfinopoulos, V., Goulioti, T., Harbeck, N., Hilal, V., Knox, S., Lemonnier, J., Ławniczak, M., Marini, L., Matos, E., Morales, P., Murray, K., Nitz, U., Passalaqua, R., Piccart, M., Remmelzwaal, J., Rubio, I., Rutgers, E., Saghatchian, M., Slaets, L., Sotiriou, C., Straehle, C., Straley, M., Theron, N., Thompson, A., Tryfonidis, K., Todeschini, R., Urunkar, M., van 't Veer, L., Viale, G., Aalders, K., Bines, J., Bedard, P., Bozovic, I., Braga, S., Castaneda, C., Celebic, A., Colichi, C., Criscitiello, C., Dal Lago, L., Demonty, G., Drukker, C., Fei, F., Lia, M., Loi, S., Messina, C., Mook, S., Moulin, C., Sreseli, R., Therasse, P., Werutsky, G., Corachan, S., Wheeler, L., Dif, N., Rizzetto, G., Beauvois, M., Meirsman, L., Breyssens, H., Decker, N., Engelen, K., Akropovic, A., Harrison, J., Henot, F., Celis, M., De Jongh, B., Delmotte, I., Daubie, V., Goossens, R., Helsen, N., Hourt, L., Janssen, S., Soete, V., Vansevenant, K., Hermans, C., Hart, G., Brink, G., Floore, A., Sixt, B., Buyse, M., van't Veer, L.J., Pierga, J.Y., Brain, E., Causeret, S., Glas, A.M., Meulemans, B., Neijenhuis, P.A., Passalacqua, R., Ravdin, P., Rubio, I.T., Smilde, T.J., Stork, L., Thomas, G., Thompson, A.M., van der Hoeven, J.M., Vuylsteke, P., and Bernards, R.

Abstract

The 70-gene signature test (MammaPrint) has been shown to improve prediction of clinical outcome in women with early-stage breast cancer. We sought to provide prospective evidence of the clinical utility of the addition of the 70-gene signature to standard clinical-pathological criteria in selecting patients for adjuvant chemotherapy. In this randomized, phase 3 study, we enrolled 6693 women with early-stage breast cancer and determined their genomic risk (using the 70-gene signature) and their clinical risk (using a modified version of Adjuvant! Online). Women at low clinical and genomic risk did not receive chemotherapy, whereas those at high clinical and genomic risk did receive such therapy. In patients with discordant risk results, either the genomic risk or the clinical risk was used to determine the use of chemotherapy. The primary goal was to assess whether, among patients with high-risk clinical features and a low-risk gene-expression profile who did not receive chemotherapy, the lower boundary of the 95% confidence interval for the rate of 5-year survival without distant metastasis would be 92% (i.e., the noninferiority boundary) or higher. A total of 1550 patients (23.2%) were deemed to be at high clinical risk and low genomic risk. At 5 years, the rate of survival without distant metastasis in this group was 94.7% (95% confidence interval, 92.5 to 96.2) among those not receiving chemotherapy. The absolute difference in this survival rate between these patients and those who received chemotherapy was 1.5 percentage points, with the rate being lower without chemotherapy. Similar rates of survival without distant metastasis were reported in the subgroup of patients who had estrogen-receptor-positive, human epidermal growth factor receptor 2-negative, and either node-negative or node-positive disease. Among women with early-stage breast cancer who were at high clinical risk and low genomic risk for recurrence, the receipt of no chemotherapy on the basis of t

Published
2016

27. 100 (PB-001) - 5-years relapse-free survival and predictive factors identification in HR-positive HER2-negative breast cancer patients treated with anastrozole or fulvestrant neoadjuvant endocrine therapy: Pooled analysis of the CARMINA02 and HORGEN phase II trials

Author

Lerebours, F., Pulido, M., Fourme, E., Debled, M., Becette, V., Bonnefoi, H., Rivera, S., Mac Grogan, G., Mouret-Reynier, M.A., Tunon de Lara, C., Pierga, J.Y., Breton-Callu, C., Venat-Bouvet, L., Mathoulin-Pelissier, S., Kerbrat, P., Dalenc, F., Sigal, B., Bachelot, T., Lemonnier, J., Lerebours, and Quenel-Tueux, N.

Published
2018
Full Text
View/download PDF

28. 1 - Trasutuzumab versus observation for high-risk, non-metastatic, HER2 non-amplified breast cancer with Circulating Tumor Cells (EORTC 90091-10093 Treat CTC): A European, multicenter, randomized phase 2 trial

Author

Ignatiadis, M., Litiere, S., Rothe, F., Riethdorf, S., Proudhon, C., Fehm, T., Aalders, K., Forstbauer, H., Fasching, P., Brain, E., Vuylsteke, P., Guardiola, E., Lorenz, R., Pantel, K., Tryfonidis, K., Janni, W., Piccart, M., Sotiriou, C., Rack, B., and Pierga, J.Y.

Published
2018
Full Text
View/download PDF

31. Prediction of axillary lymph node status in male breast carcinoma

Author

Vaysse, C., primary, Sroussi, J., additional, Mallon, P., additional, Feron, J.G., additional, Rivain, A.L., additional, Ngo, C., additional, Belichard, C., additional, Lasry, S., additional, Pierga, J.Y., additional, Couturaud, B., additional, Fitoussi, A., additional, Laki, F., additional, Fourchotte, V., additional, Alran, S., additional, Kirova, Y., additional, Vincent-Salomon, A., additional, Sastre-Garau, X., additional, Sigal-Zafrani, B., additional, Rouzier, R., additional, and Reyal, F., additional

Published
2013
Full Text
View/download PDF

34. P3.13 Immune Status Stratification of Metastatic Breast Cancer Patients: Lympho-Divpenia Predicts Overall Survival

Author

Manuarii, M., primary, Tredan, O., additional, Bachelot, T., additional, Clapisson, G., additional, Courtier, A., additional, Parmentier, G., additional, Rabeony, T., additional, Grives, A., additional, Perez, S., additional, Mouret, J.F., additional, Perol, D., additional, Chabaud, S., additional, Ray-Coquard, I., additional, Labidi-Galy, I., additional, Heudel, P., additional, Pierga, J.Y., additional, Caux, C., additional, Blay, J.Y., additional, Pasqual, N., additional, and Ménétrier-Caux, C., additional

Published
2012
Full Text
View/download PDF

35. Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab

Author

Malka, D., primary, Boige, V., additional, Jacques, N., additional, Vimond, N., additional, Adenis, A., additional, Boucher, E., additional, Pierga, J.Y., additional, Conroy, T., additional, Chauffert, B., additional, François, E., additional, Guichard, P., additional, Galais, M.P., additional, Cvitkovic, F., additional, Ducreux, M., additional, and Farace, F., additional

Published
2012
Full Text
View/download PDF

37. 13 No Axillary Surgery in Breast Cancer?

Author

Alran, S., primary, Ngô, C., additional, Reyal, F., additional, Fourchotte, V., additional, Tardivon, A., additional, Pierga, J.Y., additional, Salomon-Vincent, A., additional, and Fourquet, A., additional

Published
2012
Full Text
View/download PDF

39. 5021 POSTER DISCUSSION Multivariable Prognostic Model for Individual Survival Prediction of Metastatic Breast Cancer Patients Taking Into Account Circulating Tumour Cells (CTC) Count Before and During Chemotherapy

Author

Bidard, F., primary, Hajage, D., additional, Bachelot, T., additional, Delaloge, S., additional, Brain, E., additional, Campone, M., additional, Dieras, V., additional, Asselain, B., additional, Mathiot, C., additional, and Pierga, J.Y., additional

Published
2011
Full Text
View/download PDF

40. The EORTC 10041/BIG 03–04 MINDACT (Microarray in Node Negative and 1 to 3 Positive Lymph Node Disease May Avoid ChemoTherapy) Trial: Patients' Baseline Characteristics and Logistics Aspects After a Successful Accrual

Author

Piccart, M., primary, Bogaerts, J., additional, Cardoso, F., additional, Werutsky, G., additional, Delaloge, S., additional, Van 't Veer, L., additional, Rubio, I., additional, Moulin, C., additional, Engelen, K., additional, Viale, G., additional, Thompson, A.M., additional, Passalacqua, R., additional, Nitz, U., additional, Vuylsteke, P., additional, Pierga, J.Y., additional, and Rutgers, E., additional

Published
2011
Full Text
View/download PDF

41. 6094 POSTER Impact of Early Tumour Shrinkage on Long-term Outcome in Metastatic Colorectal Cancer (mCRC) Treated With 5FU+lrinotecan+Leucovorin (FOLFIRI) or Capecitabine+lrinotecan XELIRI Plus Bevacizumab

Author

Ichante, J.L., primary, Adenis, A., additional, Francois, E., additional, Boucher, E., additional, Pignon, J.R., additional, Ychou, M., additional, Pierga, J.Y., additional, Montotot-Grillo, C., additional, Conroy, T., additional, and Ducreux, M., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results